GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Ending Cash Position

CTOR (Citius Oncology) Ending Cash Position : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Ending Cash Position?

Citius Oncology's Ending Cash Position for the quarter that ended in Sep. 2024 was $0.00 Mil.

Citius Oncology Ending Cash Position Historical Data

The historical data trend for Citius Oncology's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Ending Cash Position Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
Ending Cash Position
- - -

Citius Oncology Semi-Annual Data
Sep22 Sep23 Sep24
Ending Cash Position - - -

Citius Oncology Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Citius Oncology's Ending Cash Position for the fiscal year that ended in Sep. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3.3306690738755E-16+-3.3306690738755E-16
=0.00

Citius Oncology's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=3.3306690738755E-16+-3.3306690738755E-16
=0.00

Citius Oncology Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Ending Cash Position
Comparable Companies
SCYX RMTI SXTC MRMD ETST CPIX ASRT INCR INIS DRRX ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
N/A
Address
11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Website
https://www.citiusonc.com
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.